We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

TD Cowen lowered the firm’s price target on BioNTech (BNTX) to $110 from $122 and keeps a Hold rating on the shares. The firm updated its model ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Other equities research analysts have also issued research reports about the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $171.44 price objective on shares of BioNTech in ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

Despite a tough start to 2025, the stock has gained about 9% in the past 12 months. U.S.-listed shares of BioNTech (BNTX) lost ground Monday, as the COVID-19 vaccine maker’s soft outlook for ...

The latest analyst coverage could presage a bad day for BioNTech SE (NASDAQ:BNTX), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little ...